Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedMay 22, 2026
DataAggregated Company Financials
Companies63
  • 7D2.4%
  • 3M-7.9%
  • 1Y7.1%
  • YTD-20.0%

In the last week, the Life Sciences industry is up 1.6%, with Danaher up 5.3%. This means that the industry has gained 7.1% over the past year. Earnings are forecast to grow by 18% annually.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 22 May 2026US$541.7bUS$150.3bUS$14.0b33.4x38.7x3.6x
Sun, 19 Apr 2026US$595.2bUS$147.9bUS$14.1b38.3x42.3x4x
Tue, 17 Mar 2026US$536.3bUS$147.8bUS$14.0b34.3x38.3x3.6x
Thu, 12 Feb 2026US$609.3bUS$147.6bUS$12.9b32.9x47.3x4.1x
Sat, 10 Jan 2026US$691.5bUS$145.8bUS$12.4b37.1x55.9x4.7x
Mon, 08 Dec 2025US$662.3bUS$145.8bUS$12.5b35.7x53.1x4.5x
Wed, 05 Nov 2025US$643.0bUS$145.5bUS$12.1b33.9x53.3x4.4x
Fri, 03 Oct 2025US$623.9bUS$144.3bUS$14.6b32.2x42.9x4.3x
Sun, 31 Aug 2025US$585.1bUS$144.3bUS$14.6b29.2x40.2x4.1x
Tue, 29 Jul 2025US$585.5bUS$143.7bUS$8.8b37.9x66.5x4.1x
Thu, 26 Jun 2025US$527.7bUS$142.9bUS$9.2b36.1x57.5x3.7x
Sat, 24 May 2025US$500.2bUS$142.8bUS$9.1b31.6x55x3.5x
Mon, 21 Apr 2025US$503.7bUS$142.6bUS$10.0b34.3x50.6x3.5x
Wed, 19 Mar 2025US$600.9bUS$143.0bUS$9.8b39x61.2x4.2x
Fri, 14 Feb 2025US$628.2bUS$143.3bUS$11.0b35.3x57.1x4.4x
Sun, 12 Jan 2025US$671.3bUS$142.4bUS$10.2b43.2x65.8x4.7x
Tue, 10 Dec 2024US$664.3bUS$142.4bUS$10.2b44.8x65x4.7x
Thu, 07 Nov 2024US$700.3bUS$142.4bUS$10.4b43.4x67.4x4.9x
Sat, 05 Oct 2024US$732.4bUS$141.8bUS$8.5b37.6x86.2x5.2x
Mon, 02 Sep 2024US$749.5bUS$141.8bUS$8.5b37.8x88.2x5.3x
Wed, 31 Jul 2024US$732.5bUS$141.0bUS$12.6b37.7x58.3x5.2x
Fri, 28 Jun 2024US$685.8bUS$141.3bUS$12.2b37.9x56.3x4.9x
Sun, 26 May 2024US$726.8bUS$141.5bUS$12.4b38.7x58.5x5.1x
Tue, 23 Apr 2024US$682.2bUS$142.0bUS$12.8b40.8x53.3x4.8x
Thu, 21 Mar 2024US$746.6bUS$142.1bUS$12.8b44.3x58.2x5.3x
Sat, 17 Feb 2024US$720.5bUS$142.2bUS$12.5b43.3x57.5x5.1x
Mon, 15 Jan 2024US$684.9bUS$153.9bUS$14.2b35.4x48.3x4.5x
Wed, 13 Dec 2023US$653.3bUS$153.7bUS$14.2b35.6x45.9x4.2x
Fri, 10 Nov 2023US$592.6bUS$153.8bUS$10.9b30.3x54.3x3.9x
Sun, 08 Oct 2023US$644.8bUS$154.6bUS$11.2b33.1x57.6x4.2x
Tue, 05 Sep 2023US$735.8bUS$154.6bUS$11.2b33.1x65.7x4.8x
Thu, 03 Aug 2023US$731.4bUS$154.6bUS$11.5b31.8x63.5x4.7x
Sat, 01 Jul 2023US$697.8bUS$152.4bUS$12.5b29.5x55.8x4.6x
Mon, 29 May 2023US$677.4bUS$152.2bUS$12.5b27.7x54.2x4.5x
Price to Earnings Ratio

54.2x


Total Market Cap: US$677.4bTotal Earnings: US$12.5bTotal Revenue: US$152.2bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 56.6x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 38.1x which is lower than its 3-year average PE of 56.6x.
  • The 3-year average PS ratio of 4.4x is higher than the industry's current PS ratio of 3.5x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 3.9% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-0.82%
Healthcare0.65%
Life Sciences2.41%
Clinical Research and Equipment2.41%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
DHR DanaherUS$173.335.3%
+US$6.2b		-7.5%PE33.4x
WST West Pharmaceutical ServicesUS$316.135.3%
+US$1.1b		51.6%PE41.2x
BIO Bio-Rad LaboratoriesUS$286.7416.4%
+US$1.1b		26.2%PE45.5x
MTD Mettler-Toledo InternationalUS$1.09k4.7%
+US$980.9m		-4.0%PE25.2x
WAT WatersUS$340.992.3%
+US$763.9m		-2.1%PE74.5x

Latest News

AVTR
US$7.87
Avantor
7D
-0.9%
1Y
-38.8%
IQV
US$168.02
IQVIA Holdings
7D
-1.6%
1Y
21.7%
Seeking Alpha • May 20

IQVIA: The Market May Be Missing The AI And Data Story

Summary IQVIA earns a Buy rating as the market underappreciates its AI-driven Commercial Solutions segment and unique healthcare data assets. AI is a tailwind, not a threat, with 19 of the top 20 pharma companies using IQV's AI agents and workflows. Commercial Solutions segment grew 11.6% year-over-year, outpacing the traditional CRO segment and driving margin expansion. Despite 4.7x net debt/EBITDA, robust free cash flow, aggressive buybacks, and hidden growth support a 60% upside to $275/share in 3 years. Read the full article on Seeking Alpha
WST
US$316.13
West Pharmaceutical Services
7D
5.3%
1Y
51.6%
A
US$114.79
Agilent Technologies
7D
1.4%
1Y
4.7%
Narrative Update • May 20

A: New Diagnostic Indications And Buybacks Will Support Future Upside Potential

Analysts have nudged their price target on Agilent Technologies slightly higher to $161.07 from $160.69, reflecting modest adjustments to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Launched the BioTek Cytation 9 cell imaging multimode reader, combining multimode microplate reading with high content cell imaging in a single platform aimed at faster, higher throughput workflows in research, pharmaceutical, and biotechnology labs (Product related announcement).
DHR
US$173.33
Danaher
7D
5.3%
1Y
-7.5%
Narrative Update • May 19

DHR: Bioprocess Recovery And Masimo Deal Set To Support Premium Multiple

Analysts have trimmed the implied fair value for Danaher by about $2 to roughly $248 per share, as they balance slightly higher long term growth and margin expectations with a lower assumed P/E multiple, evolving views on bioprocess recovery, and recent price target changes across the Street. Analyst Commentary Recent Street commentary around Danaher reflects a mixed but engaged view, with several firms adjusting price targets and reassessing how quickly the company can execute on its bioprocess ambitions and broader portfolio moves.
ATLN
US$1.35
Atlantic International
7D
-12.3%
1Y
-35.7%
BIO
US$286.74
Bio-Rad Laboratories
7D
16.4%
1Y
26.2%
WAT
US$340.99
Waters
7D
2.3%
1Y
-2.1%
Narrative Update • May 18

WAT: New Product Launches And Completed Buybacks Will Support Future Upside

Analysts now set a slightly higher price target for Waters at about $478, up from about $470, reflecting updated views on its fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Waters issued earnings guidance for the second quarter of 2026, with expected total revenue between US$1.616b and US$1.631b, and for full year 2026, with expected total revenue between US$6.405b and US$6.455b on a reported basis (Corporate guidance).
ALMR
US$22.00
Alamar Biosciences
7D
-2.3%
1Y
n/a
MTD
US$1,090.45
Mettler-Toledo International
7D
4.7%
1Y
-4.0%
Narrative Update • May 15

MTD: 2026 Local Currency Sales Outlook Will Drive Future Upside

Analysts have trimmed their price target for Mettler-Toledo International from about $1,488 to roughly $1,345, citing updated assumptions that include slightly different revenue growth, profit margin, discount rate, and future P/E expectations. What's in the News Mettler-Toledo International issued new earnings guidance for the second quarter of 2026, indicating an anticipated local currency sales increase of approximately 3% (company guidance).
RVTY
US$95.38
Revvity
7D
-1.0%
1Y
5.4%
TMO
US$449.37
Thermo Fisher Scientific
7D
0.3%
1Y
12.2%
STVN
US$17.85
Stevanato Group
7D
-0.8%
1Y
-21.1%
RGEN
US$113.37
Repligen
7D
9.7%
1Y
-5.9%
Narrative Update • May 11

RGEN: Recalibrated Street Expectations And Hubs Expansion Will Shape Long Term Outlook

Analysts now place Repligen's fair value at $142, a $2 adjustment that reflects a mix of recent price target cuts and increases as they weigh updated growth expectations, margins, and P/E assumptions from the latest round of Street research. Analyst Commentary The latest Street research on Repligen shows a split tape, with some firms lifting targets and others cutting them, which nets out to the modest US$2 bump in the aggregated fair value estimate to US$142.
FTRE
US$13.14
Fortrea Holdings
7D
-7.7%
1Y
209.9%
Narrative Update • May 07

FTRE: Execution Risk Around 2026 Revenue Guidance Will Cap Future Upside

Analysts have raised their price targets on Fortrea by $3 to $5, and the fair value estimate in this model has shifted from $5.0 to $9.5 as analysts point to moderating discount rate assumptions, slightly positive revenue growth, and higher expected profit margins reflected in a higher forward P/E multiple. Analyst Commentary Recent research on Fortrea shows a split view, with some firms raising price targets by US$3 to US$5, while others have taken a more cautious stance, trimming targets and questioning how much upside is already reflected in the valuation.
ICLR
US$116.57
ICON
7D
-0.4%
1Y
-8.2%
Narrative Update • May 06

ICLR: Site Network Expansion Will Support Recovery From Accounting Investigation

ICON's updated analyst price target has moved higher to $135.07 from $132.08 as analysts weigh recent target hikes and upgrades against ongoing accounting related concerns and more cautious growth assumptions. Analyst Commentary Street research on Icon reflects a split view, with some analysts focusing on valuation support and long term demand for clinical research, while others stay cautious around accounting risks and reduced earnings assumptions.